Recent Updates — CTY

City Therapeutics filed its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on October 19, 2026, in connection with the completion of its initial public offering. The filing authorizes 500,000,000 shares of common stock, eliminates references to previously existing preferred stock series, and authorizes 10,000,000 shares of undesignated preferred stock issuable at the Board's discretion. It also removes the ability for stockholders to take action by written consent. Concurrently, the Amended and Restated Bylaws became effective on October 15, 2026, establishing advance notice procedures for stockholder proposals and board nominations. City Therapeutics is a biotechnology company focused on developing targeted therapies.